amyloid-beta peptide 40/42 in plasma

From Aaushi
Jump to navigation Jump to search

Indications

Clinical significance

* authors suggest plasma Abeta40/42 may be used to identify people at risk of cognitive decline [2.3]

* it is difficult to reconcile this with comments in ref[1]

Methods

More general terms

Additional terms

Component of

Components

References

  1. 1.0 1.1 1.2 Nakamura A, Kaneko N, Villemagne VL et al High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature. 2018 Feb 8;554(7691):249-254 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29420472 https://www.nature.com/articles/nature25456
  2. 2.0 2.1 Giudici KV, de Souto Barreto P, Guyonnet S et al Assessment of Plasma Amyloid-beta42/40 and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Netw Open. 2020;3(12):e2028634 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33331917 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774284
  3. Pereira JB et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain 2021 Jun 2; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34077494 https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab163/6291241
  4. 4.0 4.1 Janelidze S, Teunissen CE, Zetterberg H et al Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease. JAMA Neurol. Published online September 20, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34542571 https://jamanetwork.com/journals/jamaneurology/fullarticle/2784411
  5. 5.0 5.1 Dark HE, Paterson C, Daya GN et al Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk. Ann Neurol. 2023. Oct 6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37801487 https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26817